| Feline infectious peritonitis | |
|---|---|
 | |
| FIP-infected kidney showing inflammatory response | |
| Specialty | Infectious diseases  |
| Symptoms | Initial phase: common cold-like symptoms.
Later on: ataxia, muscle weakness, dysphagia. End phase: shortness of breath, urinary incontinence, paralysis. |
| Usual onset | Can take up to a year for symptoms to appear after exposure to virus |
| Duration | 1-month or less average life expectancy after diagnosis, especially in kittens |
| Causes | Mutation of feline coronavirus |
| Treatment | UK, Australia, Netherlands: GS-441524 (given orally as tablets) and its parent drug remdesivir (given by intravenous or subcutaneous injection)[1][2][3][4] |
| Prognosis | Usually fatal without treatment, but with GS-441524 treatment over 80% of treated cats make a full recovery. |
| Frequency | Common |
Feline infectious peritonitis (FIP) is a common and aberrant immune response in cats to infection with feline coronavirus (FCoV).[5]
- ^ Hartmann 2017. Coronavirus Infections (Canine and Feline), Including Feline Infectious Peritonitis. Chapter 224 p984-991. In Textbook of Internal Medicine, 4th Edition. Ettinger.
- ^ Kennedy and Little 2012. Infectious diseases, Chapter 33 p1038-1047. In The Cat. Clinical Medicine and Management, Little.
- ^ Pederson et al 2019. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg.21: 271–281
- ^ Dickinson et al 2020. Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis J Vet Intern Med. 2020 Jul; 34(4): 1587–1593
- ^ Addie, D.; Belák, S.; Boucraut-Baralon, C.; Egberink, H.; Frymus, T.; Gruffydd-Jones, T.; Hartmann, K.; Hosie, M. J.; Lloret, A. (11 July 2009). "Feline infectious peritonitis. ABCD guidelines on prevention and management". Journal of Feline Medicine and Surgery. 11 (7): 594–604. doi:10.1016/j.jfms.2009.05.008. PMC 7129471. PMID 19481039.